NCT06393803 - Phase 1 Study of KH607 Tablets | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 21, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions

Healthy

Interventions

DRUG

2mg KH607 tablets

Subject receive KH607 tablets or placebo orally single dose.

DRUG

5mg KH607 tablets

Subject receive KH607 tablets or placebo orally single dose.

DRUG

10mg KH607 tablets

Subject receive KH607 tablets or placebo orally single dose or multiple doses.

DRUG

20mg KH607 tablets

Subject receive KH607 tablets or placebo orally single dose or multiple doses.

DRUG

30mg KH607 tablets

Subject receive KH607 tablets or placebo orally single dose or multiple doses.

DRUG

40mg KH607 tablets

Subject receive KH607 tablets or placebo orally single dose.

DRUG

50mg KH607 tablets

Subject receive KH607 tablets or placebo orally single dose.

DRUG

60mg KH607 tablets

Subject receive KH607 tablets or placebo orally single dose.

Trial Locations (1)

RECRUITING

Beijing Anding Hospital Affiliated to Capital Medical University, Beijing